MSC Therapy for Shoulder Injuries
Patient progression report covering 228 patients treated for upper-limb overuse and degenerative shoulder pathologies between January 2022 and April 2023.
228
Patients Treated
53% both shoulders treated
Jan 2022 – Apr 2023
Study Period
Clinical care program follow-up
4
Pathologies Covered
Rotator cuff, labrum, OA, bursitis
+31%
SF-12 Physical Gain
Overall improvement at 12 months
Clinical Care Program Overview
From January 2022 to April 2023, 228 patients were treated for shoulder pathologies, including bilateral cases and unilateral left- and right-side presentations. The report covers rotator cuff pathology, labral injury, shoulder osteoarthritis, and bursitis.
Outcomes were tracked using validated instruments including the Visual Analogue Scale (VAS), DASH questionnaire, and SF-12 health survey. Patients consented to longitudinal follow-up through a secure clinical data platform.
Pathology Distribution
Key Outcome Snapshot
SF-12 Physical
+15.98 points (31%)Pre-therapy: 50.16 · 6 months: 64.16 · 12 months: 67.14
SF-12 Mental
+12.39 points (21%)Pre-therapy: 58.56 · 6 months: 69.59 · 12 months: 70.95
Follow-up Response Rates by Pathology
| Pathology | Pre-therapy | 6 months | 12 months |
|---|---|---|---|
| Rotator cuff tendinopathy and tears | 96 (100%) | 74 (77%) | 71 (74%) |
| Shoulder osteoarthritis | 70 (100%) | 54 (77%) | 51 (73%) |
| Labrum injury | 72 (100%) | 53 (74%) | 53 (74%) |
| Shoulder bursitis | 41 (100%) | 34 (83%) | 28 (68%) |
Methodology & Clinical Notes
Assessment Instruments
Pain was assessed with the Visual Analogue Scale (VAS), disability with the DASH questionnaire, and health-related quality of life with the SF-12 survey across physical and mental domains.
Patient Cohort
Treatment-side distribution in the cohort was 53% both shoulders, 23% left shoulder only, and 24% right shoulder only. The report focuses on clinically observed progress through pre-therapy, 6-month, and 12-month checkpoints.
Interpretation
Across combined shoulder injuries, the reported SF-12 scores show improved physical and mental quality-of-life measures over the follow-up period, supporting continued monitoring of this patient group.
Selected References
- Patel M, Amini MH. Management of Acute Rotator Cuff Tears. Orthop Clin North Am. 2022 Jan;53(1):69-76.
- Jain A, Aniq H, Mistry A. SLAP Injury and the Superior Labrum. Semin Musculoskelet Radiol. 2022 Oct;26(5):577-584.
- Stanborough RO, Bestic JM, Peterson JJ. Shoulder Osteoarthritis. Radiol Clin North Am. 2022 Jul;60(4):593-603.
- Lanham NS, Swindell HW, Levine WN. The Subacromial Bursa: Current Concepts Review. JBJS Rev. 2021 Nov 10;9(11).
Reports from our scientific and medical staff are prepared to provide objective assessments on patient outcomes using widely accepted research methodologies. Individual results may vary. Read our full medical disclaimer.
Considering MSC Therapy for Shoulder Injuries?
Schedule a no-obligation consultation with our specialists to discuss whether regenerative medicine may be appropriate for your shoulder condition.
Or call directly: +90 534 856 92 92